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Pilot study of the use of community volunteers
to distribute azithromycin for trachoma control
in Ghana
Anthony W. Solomon,1 Joseph Akudibillah,2 Peter Abugri,2 Maria Hagan,3 Allen Foster,1 Robin L. Bailey,1
& David C.W. Mabey1
Objective To assess the skills of community health volunteers in diagnosing active trachoma and distributing
azithromycin in the Northern Region of Ghana.
Methods Six community health volunteers from Daboya were trained to diagnose trachoma and to treat the
disease using azithromycin. They were also informed of the drug’s possible side-effects. Under supervision, each
volunteer then examined, and if necessary treated, 15 households. The dose of azithromycin was determined by
weight; height was also measured. Tablets were given in preference to suspension when possible.
Results The volunteers’ diagnostic sensitivity for active trachoma was 63%; their specificity was 96%. At the
household level, their ‘‘decision to treat’’ was correct in 83% of households. In 344 treatment episodes, volunteers
planned a dose of azithromycin outside the range 15–30 mg/kg on only seven occasions (2.0% of all planned
treatments). The volunteers’ drug management skills were good, the response of the community was excellent, and
adverse reactions were infrequent. Diagnosis of active trachoma, record-keeping skills, and knowledge of side-effects
were found to need greater emphasis in any future education programme. Most people aged four years or older were
able to swallow tablets. For those taking tablets, the correlation between the data gathered for height and weight
shows that calculating azithromycin doses by height is a valid alternative to calculating it by weight.
Conclusion Trained community health volunteers have a potential role in identifying active trachoma and
distributing azithromycin. To simplify training and logistics, it may be better to base dosage schedules on height rather
than weight for those taking tablets, which included most people aged four years or more in the population studied.
Keywords: trachoma, diagnosis, drug therapy; azithromycin, therapeutic use; community health aides, education;
Ghana.
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Introduction
Trachoma is the world’s leading cause of preventable
blindness. Estimates suggest that 5.6 million people
worldwide are already blind because of the disease,
while another 146 million people may have active
infection (1). The World Health Organization has
recently adopted the ‘‘SAFE’’ strategy, with the aim
of eliminating trachoma as a disease causing blind-
ness by the year 2020 (2). The strategy is four-
pronged: Surgical correction of trichiasis, Antibiotics
for active trachoma, Face washing, and Environ-
mental improvement (provision of latrines, control
of flies, and related interventions).
With respect to antibiotic treatment, several
studies have shown that a single or multiple dose of
oral azithromycin is as effective in eliminating active
trachoma as prolonged courses of tetracycline eye
ointment (3–6). A randomized controlled trial com-
paring azithromycin with topical tetracycline given as a
community-wide treatment for trachoma in the
Gambia has revealed a favourable profile of side-
effects for azithromycin (7). The main disadvantage of
using azithromycin to control trachoma is its relatively
high cost, which, at US$ 7–14 a dose, is too high for
most countries where trachoma is endemic.
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Ghana has been chosen by the International
Trachoma Initiative as one of five countries to
receive a donation of azithromycin for the control of
trachoma. To use this donation effectively it is
necessary to determine how to distribute the drug
safely and efficiently. There is an ongoing effort to
eradicate guinea-worm disease in Ghana using
volunteers from the community. A group of these
volunteers from the Daboya subdistrict of the West
Gonja district, Northern Region, has previously
undergone training in the recognition of trachoma
and its treatment with topical tetracycline. This report
describes an operational study to assess the skills of
community health (guinea-worm disease control)
volunteers in diagnosing active trachoma, and to
examine the feasibility of using them to distribute
azithromycin for control of trachoma in Ghana.
Additionally, to explore the logistics of azithromycin
distribution, the proportion of children requiring
tablets rather than suspension, as well as the
correlation between height andweight in the treatable
population, are analysed.
The objectives of the study were:
. to test the ability of community health volunteers
to diagnose active trachoma accurately and to
identify households requiring antibiotic treatment;
. to test the ability of community health volunteers
to give the correct dose of azithromycin by weight
to children and adults;
. to test the ability of community health volunteers
to keep records of tablets received and distributed;
. to assess the incidence of possible adverse
reactions to the azithromycin treatment delivered
by the volunteers;
. to document the response of communities to
trachoma diagnosis and antibiotic distribution
being undertaken by the volunteers;
. to test the feasibility of giving azithromycin tablets
to preschool children;
. to examine the relationship between height and
weight in those requiring azithromycin for
trachoma control.
Methods
Daboya is one of six subdistricts of the West Gonja
district. In 1996, Daboya’s 54 villages were estimated
to accommodate some 28 714 people (8). Most live in
traditional family compounds, surviving primarily by
subsistence farming. The subdistrict is serviced by a
single health clinic staffed by twomedical assistants, a
disease control officer, and a midwife. There are two
ophthalmic nurses based in Damango Hospital, the
main health care facility for the West Gonja district.
Six community health volunteers (fivemen and
one woman) from Daboya were given training in the
diagnosis of trachoma, in the SAFE strategy, and in
the use of azithromycin (including the drug’s side-
effects). The education sessions extended over four
days in late June 1999. The six volunteers had each
participated in 7–18 days’ training in trachoma before
these four days, and were already working as
‘‘trachoma volunteers’’, distributing tetracycline eye
ointment to people in their villages.
After training, each volunteer was asked to
examine the members of 15 households in the
presence of a supervisor (doctor or ophthalmic
nurse). The volunteer was expected to examine both
upper tarsal conjunctivae of all available members of
the household who were aged one year or more.
Handheld battery-powered monocular loupes were
supplied. The supervisor examined all members of
the household independently.
The volunteers were required to treat all
members of any household in which there were
one or more cases of active trachoma. Using the
simplified trachoma grading scheme, these were
designated as TF (the presence of trachoma follicles
— ‘‘white dots’’) and TI (inflammatory trachoma
causing obscuration of more than 50% of the deep
tarsal blood vessels— ‘‘invisible blood pipelines’’)(9).
When the volunteer and the supervisor had seen all
members of a household, the volunteer was asked
whether he or she felt that the household needed
treatment. Where the volunteer and the supervisor
disagreed, the supervisor looked at the volunteer’s
records and selected a patient or patients for re-
examination.
In households needing treatment, community
health volunteers were expected to weigh all subjects
and to determine the appropriate dose of drug for
each person, using tables that were supplied.
Analogue scales that had been obtained locally were
provided for volunteers. Supervisors independently
recorded each individual’s weight and calculated the
appropriate drug dose. Additionally, to enable weight
and height data to be compared at a later time,
supervisors measured the height of each person in
treatable households.
Azithromycin (Zithromax, Pfizer, New York)
was given as a single oral dose of about 20mg/kg, to a
maximum of 1000 mg. Individuals weighing more
than 10 kg were offered tablets. Children weighing
less than 10 kg, and heavier children whowere unable
to take tablets, were given the drug in the form of a
suspension. Pregnant women with active trachoma
were treated with 1% tetracycline eye ointment twice
daily for six weeks rather than with azithromycin.
Pregnant women in treated households who did not
themselves have active trachoma received no treat-
ment. Where volunteers neglected to ask about
pregnancy or determined an incorrect dose, they
were stopped by the supervisor when the drug was
about to be given to the patient. In this way they were
given the maximum time to correct their own errors,
so that the nature and rate of errors that might occur
if the volunteers were unsupervised could be
determined.
Before the start of fieldwork, each volunteer
was given a defined quantity of azithromycin. When
the volunteer completed examination of 15 house-
holds, he or she had to fill in an accounting form
showing the number of tablets and number of
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millilitres of suspension used in each household, to
compare the quantities of drug used with the
quantities returned, and explain any surplus or
shortfall. Volunteers were able to refer only to their
own records for this task.
Two to four days after receiving treatment,
members of households were revisited by volunteers.
Household members were questioned about symp-
toms since treatment, using open-ended questions
(‘‘Have you suffered any illness since you received the
drug?’’) and specific questions about diarrhoea,
nausea, vomiting, abdominal pain, itch, and rash.
Data were analysed using EpiInfo 6.04.
Results
Endemicity of active disease
A total of 675 householders were examined in
90 households. The supervisors identified 92 pa-
tients with active trachoma (TF and TI). The
endemicity of active disease by age and sex is shown
in Fig. 1.
Ability to diagnose active trachoma
Thirty-four of 92 cases of active trachoma were
missed by the volunteers. They also diagnosed TF
and TI in 24 of 583 people who had no signs of active
disease. Their diagnostic sensitivity was 63%; their
specificity was 96%.
Azithromycin was distributed to all members
of any household in which there was one or more
cases of active trachoma. For operational purposes,
in addition to the diagnostic reliability for individual
patients, the decision of the volunteer to treat or not
treat the entire household was of interest. The
volunteers’ ‘‘decision to treat’’ the household before
discussion with the supervisor was correct in 75 of
90 households visited (83%; percentages for the six
volunteers were 53, 87, 87, 87, 93 and 93).
Of the 15 incorrect decisions to treat, there were
seven instances of planning no treatment for house-
holds in which treatment was needed, and eight of
planning treatment where it was not needed. Collec-
tively, these households contained 61 and 68 people
respectively. In the seven ‘‘missed treatment’’ house-
holds there were 11 individuals with signs of active
trachoma. If the one volunteer who had most trouble
diagnosing active trachoma had been excluded from
fieldwork, the decision to treat would have been
incorrect for only eight households of 75.
Ability to give the correct dose
Of 90 households visited, 40 housed people with
signs of active disease. The six volunteers collectively
determined dosages for 344 individuals in these
40 households; 322 (93.6%) were correct. Four of
the incorrect dose determinations consisted of
offering the correct dose in the form of suspension
to patients who were able to take tablets. Eleven
errors out of 22 involved a minor dose error, with the
planned dose lying in the range 15–30 mg/kg; three
of these resulted from determining the weight of the
patient incorrectly, the dose determined by the
volunteer being correct for the weight they had rec-
orded. In only four of 344 calculations for doses did
the volunteers plan a dose that exceeded 30 mg/kg
actual body weight. Only three planned doses were
below 15 mg/kg body weight.
Ability to keep records of tablets received
and distributed
Several volunteers found keeping records difficult.
When children were unable to take the tablets
offered, volunteers often forgot to record that
suspension had been used instead. Similarly, when a
tablet was refused but wasted in the process (for
example, spat out), volunteers were sometimes seen
to cross out the mark showing that a tablet had been
given before recording the volume of suspension
administered. This complicated their efforts to
account for how the azithromycin had been used.
Of six volunteers, only two kept accurate
records of tablets distributed and returned a balance
of tablets that their paperwork showed to be the
correct amount. Four of the six returned a volume of
suspension within 5 ml of the calculated ‘‘correct’’
amount. Each of the volunteers managed the
azithromycin carefully and returned all of the unused
drug. Unfortunately, they were often not able to
prove this from their own notes.
Adverse reactions
The concept of side-effects was a new one to most of
the volunteers, and some had trouble remembering to
warn households about the possible risks of azithro-
mycin before offering the drug. When adverse events
were reported at the follow-up visit, the volunteers had
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difficulty distinguishing patients with persistent or
potentially more serious events from those whose
symptoms had abated or were abating. Thirty patients
(22 males and 8 females) reported adverse events at
follow-up (8.8%). Twenty-seven of these patients (or
their parents) attributed symptoms to azithromycin,
and three to malaria or other illness. By the time of the
follow-up visit, only three of the 30 had continuing
symptoms: an 8 year-old boy, whose pruritic red rash
was gradually subsiding, and two men aged 35 and 40
who had persistent diarrhoea.
A summary of adverse effects encountered is
presented in Table 1. Two treated individuals
reported resolution or improvement of systemic
symptoms after taking azithromycin: an 80-year-old
man whose genitourinary symptoms resolved, and a
two-year-old girl whose parents reported an
improvement in pre-existing diarrhoea.
Community response
The study period coincided with the beginning of the
wet season — a critical time to plant crops. Despite
this, community response to the (often time-
consuming) visits was almost always positive. Only
one adult and six children (1% of eligible house-
holders) refused to be examined.
One household of eightmembers, including one
person who showed signs of active trachoma, refused
treatment after being examined, weighed, and mea-
sured, on the grounds that it would further delay their
departure to the fields. Three people from separate
households left for farming duties while their families
were receiving treatment and did not take the
azithromycin that had been planned for them.
Using azithromycin tablets in preschool children
Of 341 treated patients, 294 (86.2%) were able to
take tablets, and 47 (13.8%) took suspension. All
treated individuals over six years of age took tablets.
All those less than two years of age required
suspension. The dosage form used for children
between two and six years old is shown in Table 2.
The relation between height and weight
Data on height and weight were available for
355 peoplea in treatable households (households in
which at least one case of active trachoma was
identified). Fig. 2 presents a logarithmic plot of these
data.
Using this log transformation, height cut-offs
for doses of one, two, three, and four tablets are
calculated as 83.4 cm, 102.3 cm, 124.5 cm, and
146.9cm.b People less than 83.4 cm tall would be
assigned to receive suspension (zero tablets), those
83.4–102.3 cm would receive one tablet, and so on.
The correlation between doses determined by weight
and by height for all 355 people is shown in Table 3.
For those people whose weight and height
readings were captured in this study, then, using the
above height cut-offs to determine the number of
tablets given results in the correct dosing of 296 of
355 cases (83.4%). Fifty-nine patients (16.6%)would
have been overdosed or underdosed — none by
more than one 250 mg tablet. Using height or length
to predict doses of suspension for children was less
reliable.
Discussion
The recent commitment by the manufacturer to
donate azithromycin to five countries with endemic
trachoma provides the opportunity to reduce the
prevalence of the infection dramatically, providing the
drug is appropriately distributed to the community.
The volunteers in this study all felt confident that the
diagnosis of trachoma and distribution of azithromy-
cin were tasks within their capabilities. The findings
support that self-assessment, with several caveats.
Several elements of the study’s design should
be interpreted with caution. Our coverage of the
communities visited was by no means complete.
Often several members of the household, and
occasionally whole compounds, were away farming
at the time of our visit. The remaining individuals did
not represent a random sample of the community,
and our ‘‘endemicity’’ data therefore lack the
Table 1. Summary of reported side-effects (not all attributed
to azithromycin)
Symptom (No. of patients) Duration (No. of days)
1 2 3 >3
Any illness 20 5 2 3
Fever 1 0 0 0
Diarrhoea 14 4 0 2
Vomiting 5 0 0 0
Abdominal pain 2 1 0 0
Dizziness 1 1 0 0
Weakness 0 1 1 0
Pruritus 2 1 1 1
Rash 0 0 0 1
Arthralgia 1 0 0 0
a This includes the 344 patients for whom doses were determined
minus a 15-year-old paraplegic girl who could not be weighed but
who did receive azithromycin, plus the eight members of the household
that declined treatment after their weights and heights were measured,
and four pregnant women. The supervisors’ height and weight
observations were used for analysis.
b The formula for derivation was log10wt = 2.426(log10ht) – 3.66.
Table 2. Form of azithromycin dosage used for treated individuals
aged 2–6 years
Age (years) 2 3 4 5 6
No. of individuals taking 18 (72) 7 (39) 5 (17) 2 (17) 1 (4)
suspension (%)
No. of individuals taking 7 (28) 11 (61) 24 (83) 10 (83) 22 (96)
tablets (%)
Total no. of individuals 25 18 29 12 23
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epidemiological validity needed for a label of
trachoma ‘‘prevalence.’’ Similarly, at the follow-up
visits, it was unusual to be able to question each
person who had received azithromycin. As a result,
we were often forced to rely on the report of available
family members on side-effects experienced by
others in the compound. The analysis of the
volunteers’ ability to diagnose active trachoma
assumes that the supervisors’ assessments were
correct in every instance. However, no mechanisms
were put in place to validate their observations.
Working independently, the volunteers’ ‘‘deci-
sion to treat’’ was correct in 83% of households.
Diagnostic reliability on a subject-by-subject basis,
however, was less impressive. In a setting with
different prevalence of trachoma or household
composition variables, the results for the ‘‘decision
to treat the household’’ might not be so encouraging.
On the other hand, if azithromycin was scheduled for
community-wide distribution, diagnostic skills would
not necessarily be required. In 344 treatment episodes,
volunteers planned a dose of azithromycin outside the
range 15–30 mg/kg on only seven occasions (2.0% of
all planned treatments). Their drug management skills
were good, and although their record-keeping skills
were not, this probably reflects supervisors’ assump-
tions that the task would be straightforward, with the
resultant failure to emphasize record-keeping proce-
dures during training. Community acceptance of the
volunteers’ role was high.
If further trials are attempted, a longer period
of volunteer training is recommended. In hindsight,
six rather than four days would have been more
appropriate for the group of volunteers who took
part in this study. For community health volunteers
not previously given training in trachoma, three to
four weeks’ training might be needed.
During training, a greater emphasis on the
clinical signs of TF, TI and TT (trichiasis— eyelashes
touching the globe or evidence of epilation) is
recommended. Teaching volunteers about TS (scar-
ring of the tarsal conjunctiva — ‘‘white lines’’) and
CO (corneal opacity) could probably be omitted. In
the absence of other signs of trachoma, neither TS
nor CO indicates the need for treatment or referral as
part of the SAFE strategy, and presenting this
Table 3. Number of individuals to receive doses of azithromycin
(comparison of dosage calculated by weight and by height)
Dose calculated Dose calculated by height
by height
0 tablet 1 tablet 2 tablets 3 tablets 4 tablets Total
0 tablet 17 2 0 0 0 19
1 tablet 14 50 11 0 0 75
2 tablets 0 4 48 13 0 65
3 tablets 0 0 1 35 14 50
4 tablets 0 0 0 0 146 146
Total 31 56 60 48 160 355
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material takes up time that could be used more
effectively elsewhere. It is further recommended that
instructions on how to record the use of azithromy-
cin for both administered and wasted drugs be made
more explicit in future education programmes.
Practice at recording treatment scenarios likely to
be encountered in the field (for example, a child
requiring a second dose of tablets after spitting out
the first) would be valuable. Similarly, more time
needs to be spent on teaching volunteers about the
side-effects of azithromycin and how to advise
householders who are to receive the drug.
Most children aged four years or older were
able to swallow Zithromax tablets. If this result were
generally true of communities where trachoma is
endemic, the task of distributing azithromycin would
be made marginally easier. Particularly in remote
communities, tablets are more readily transported,
prepared, and administered than suspension.
Determining drug dosage by body weight
proved to be problematic. The volunteers were initially
unfamiliar with the technique for making a reading on
an analogue scale, and found it difficult to calculate
weight for small children who could not stand
unsupported on the weighing platform. Ensuring that
each of our volunteers was able to determine body
weight reliably occupied a considerable proportion of
the allotted training period. The scales themselves
were bulky, and they performed poorly once dirt from
the floors of compounds made its way into the
mechanism. The good correlation between height and
weight data for those people who needed treatment
suggests that calculating azithromycin doses by height
is a valid alternative for those taking tablets. In
practice, the use of a foldingmeasuring stick graduated
in number of tablets rather than centimetres would be
best, since it would eliminate the need for a conversion
table. A spring scale with a hook and sling could be
used to weigh children who needed the drug in the
form of the suspension. If it were felt necessary to
calculate doses by weight for all, the use of electronic
scales would be preferable to analogue scales.
Conclusion
This study provides encouraging evidence that
selected, trained community health volunteers may
be able to diagnose active trachoma and distribute
azithromycin for its control. Additionally, data from
the small series of individuals treated as part of this
study support the hypothesis that it may be possible to
use height safely to determine azithromycin dosage for
individuals taking tablets, including most people aged
four years of age and above. Further work to evaluate
the potential of these approaches seems justified. n
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Re´sume´
Etude pilote sur le recours a` des volontaires appartenant a` la communaute´ pour
la distribution d’azithromycine dans la lutte contre le trachome au Ghana
Objectif Evaluer l’aptitude de volontaires appartenant
a` la communaute´ a` diagnostiquer le trachome actif et a`
effectuer la distribution d’azithromycine dans la Re´gion
Nord du Ghana.
Me´thodes Six volontaires appartenant a` la commu-
naute´ de Daboya ont e´te´ forme´s au diagnostic du
trachome et a` son traitement par l’azithromycine. Ils ont
e´galement e´te´ informe´s des e´ventuels effets secondaires
du me´dicament. Chaque volontaire a ensuite, sous
surveillance, examine´ et si ne´cessaire traite´ 15 me´nages.
La dose d’azithromycine e´tait de´termine´e d’apre`s le
poids du malade, dont le volontaire mesurait e´galement
la taille. Si possible, le me´dicament e´tait administre´ sous
forme de comprime´s plutoˆt que de suspension.
Re´sultats La sensibilite´ du diagnostic du trachome actif
par les volontaires e´tait de 63 %, et sa spe´cificite´ de
96 %. Au niveau des me´nages, la « de´cision de traiter »
e´tait correcte dans 83 % des cas. Sur 344 e´pisodes de
traitement, les volontaires n’ont pre´vu une dose
d’azithromycine tombant en dehors de la gamme 15–
30 mg/kg que dans 7 cas (2,0 % de l’ensemble des
traitements pre´vus). Les compe´tences des volontaires en
matie`re de gestion du me´dicament e´taient bonnes, la
re´ponse de la communaute´ excellente et les re´actions
inde´sirables rares. A l’avenir, les programmes pe´dago-
giques devraient insister davantage sur le diagnostic de
trachome actif, la tenue des dossiers et les effets
secondaires. De`s l’aˆge de 4 ans, la plupart des malades
sont capables d’avaler des comprime´s. Lorsque
l’azithromycine est administre´e sous forme de compri-
me´s, la corre´lation entre les donne´es rassemble´es selon
la taille ou selon le poids montre qu’il est tout aussi
valable de calculer les doses en fonction de la taille qu’en
fonction du poids.
Conclusion Apre`s formation, des volontaires apparte-
nant a` la communaute´ peuvent jouer un roˆle utile en
identifiant les cas de trachome actif et en proce´dant a` la
distribution d’azithromycine. Pour simplifier la formation
et la logistique, il pourrait eˆtre pre´fe´rable de baser le
calcul de la posologie sur la taille plutoˆt que sur le poids
pour les malades prenant des comprime´s, c’est-a`-dire, si
l’on se re´fe`re a` la population e´tudie´e, la plupart des
malades a` partir de 4 ans.
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Resumen
Estudio piloto del uso de voluntarios de la comunidad para distribuir azitromicina contra
el tracoma en Ghana
Objetivo Evaluar las aptitudes de voluntarios de salud
de la comunidad para diagnosticar el tracoma activo y
distribuir azitromicina.
Me´todos Se ensen˜o´ a seis voluntarios de salud de la
comunidad de Daboya a diagnosticar el tracoma y a
tratarlo con azitromicina. Se les informo´ tambie´n de los
posibles efectos colaterales del medicamento. Tras esa
capacitacio´n, y siempre bajo supervisio´n, cada voluntario
visito´ y examino´ 15 hogares, aplicando el tratamiento
cuando lo considero´ necesario. La dosis de azitromicina
se determino´ en funcio´n del peso; tambie´n se midio´ la
talla. En la medida de lo posible se administraron
comprimidos antes que la suspensio´n del medicamento.
Resultados La sensibilidad diagno´stica de los volun-
tarios para el tracoma activo fue del 63%; y su
especificidad, del 96%. En los hogares, su «decisio´n
de tratar» fue correcta en un 83% de los casos. De un
total de 344 episodios de tratamiento, so´lo en siete
ocasiones (2,0% de todos los tratamientos previstos) los
voluntarios calcularon una dosis de azitromicina no
comprendida entre 15 y 30 mg/kg. Los voluntarios
demostraron desenvolverse bien con los fa´rmacos, la
respuesta de la comunidad fue excelente, y las reacciones
adversas fueron infrecuentes. Hubo que admitir que en el
futuro los programas de educacio´n habrı´an de hacer ma´s
hincapie´ en el diagno´stico del tracoma activo, en las
aptitudes para la anotacio´n de los datos y en el
conocimiento de los efectos secundarios. La mayorı´a de
las personas de cuatro o ma´s an˜os eran capaces de
tragarse los comprimidos. Entre quienes utilizaron
comprimidos, la correlacio´n entre los datos referentes a
la estatura y al peso muestra que el ca´lculo de las dosis de
azitromicina en funcio´n de la talla es una alternativa
va´lida al ca´lculo en funcio´n del peso.
Conclusio´n Los voluntarios de salud de la comunidad,
debidamente capacitados, pueden ser una ayuda
adicional para identificar el tracoma activo y distribuir
azitromicina. A fin de simplificar la capacitacio´n y la
logı´stica, conviene quiza´ basar las pautas de dosificacio´n
en la estatura en lugar del peso entre quienes tomen
comprimidos, lo que significa la mayorı´a de las personas
de cuatro o ma´s an˜os de edad en la poblacio´n estudiada.
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